FCT: DCV - Outros
URI permanente para esta coleção:
Navegar
Entradas recentes
- EditorialPublication . Morais, Tânia S.; Fernandes, Alexandra R.; Baptista, Pedro V.; Gambino, Dinorah; UCIBIO - Applied Molecular Biosciences Unit; DCV - Departamento de Ciências da Vida; Frontiers Media
- EditorialPublication . Simões, Isaura; Voth, Daniel E.; Mota, Luís Jaime; UCIBIO - Applied Molecular Biosciences Unit; DCV - Departamento de Ciências da Vida; Frontiers Media
- EditorialPublication . Videira, Paula Alexandra; Borghesi, Marco; Singer, Eric A.; DCV - Departamento de Ciências da Vida; UCIBIO - Applied Molecular Biosciences Unit; Frontiers MediaGenitourinary cancers are known as significant causes of mortality worldwide. This heterogeneous group includes, among others, the most common cancer in men, prostate cancer, the most common form of kidney cancer, renal cell carcinoma (RCC), and the 10th most common cancer, bladder cancer. These entities present biological diversity with various histological subtypes and a poor prognosis when metastatic. There has been considerable progress in treating patients with genitourinary cancers due to the improved understanding of their pathological mechanisms and the identification of meaningful biomarkers. The treatment progress has led to a fundamental paradigm shift in treatments. For example, our current understanding of the immunogenicity of these tumours has improved tremendously. Thanks to that, today, immunotherapy is a reliable strategy to improve the outcomes of patients with metastatic urothelial carcinoma, renal cell carcinoma, and prostate cancer. However, there is still a critical need to enrich our understanding of additional molecular mechanisms. Along with the mechanisms, there is an urgent requirement to identify novel biomarkers to progress the diagnosis and prognosis of genitourinary cancers and their treatment. Biomarkers have become a significant focus of research, primarily on how they can help predict response to systemic therapy, identify treatment resistance, and avoid toxicities. Biomarkers that reveal the mutated tumour suppressor genes, the altered signalling pathways and the aberrantly expressed molecules help select potentially responsive patients to a given therapy. In this way, biomarkers improve outcomes and reduce costs related to ineffective treatments, and, most importantly, they significantly upsurge patients’ quality of life. This Research Topic named Biomarkers in Genitourinary Cancers includes an interesting and up to date palette of publications from prominent research and clinical groups focused on identifying significant and emerging prognostic and predictive biomarkers. These biomarkers encompass non-coding RNA, serum proteins, gene expression, and glycans, among other entities identified in patients’ cohorts, samples and in the increasing number of public databases.
- The genetic susceptibility linking preterm birth and periodontal disease a reviewPublication . Couceiroa, Joana; Grosso, Ana Rita; Baptista, Pedro V.; Mendes, Jose J.; Fernandes, Alexandra R.; Quintas, Alexandre; DCV - Departamento de Ciências da Vida; UCIBIO - Applied Molecular Biosciences Unit; Taylor & Francis
- Corrigendum to “Neurotoxic effects of MPTP on mouse cerebral cortex: Modulation of neuroinflammation as a neuroprotective strategy” [Mol. Cell. Neurosci., Volume 96, April 2019, Pages 1–9.](S1044743118303907)(10.1016/j.mcn.2019.01.003)Publication . Mendes, Mariana Oliveira; Rosa, Alexandra Isabel; Carvalho, Andreia Neves; Nunes, Maria João; Dionísio, Pedro; Rodrigues, Elsa; Costa, Daniela; Duarte-Silva, Sara; Maciel, Patrícia; Rodrigues, Cecília Maria Pereira; Gama, Maria João; Castro-Caldas, Margarida; DCV - Departamento de Ciências da Vida; UCIBIO - Applied Molecular Biosciences Unit; Academic Press Inc | Elsevier ScienceThe authors regret that in the original article there is an error in Fig. 5. Panel 5E incorrectly shows a blot for β-Actin that does not match the p-CREB blot shown above it. Nevertheless, this error does not affect the data presented in the original histogram, since quantifications of p-CREB and β-Actin were performed in the appropriate blots, corresponding to at least three independent experiments. Therefore, the histogram, image of the blot incubated with anti-p-CREB, and Figure legend are maintained. A corrected version of Fig. 5E is presented below. The authors state that this error does not change the scientific conclusions of the article in any way. [Figure presented] The authors would also like to clarify the readers that since the same gel/ membrane was used to probe for different proteins, they all share the same β-Actin blot as a loading control. This is the case of Figs. 1B, 2B, 3B and 4D (long-term treatments), Figs. 2A and 3A (short term treatments), and Fig. 5A and D (BV2 cells), where the correspondent β-Actin was used as a loading control in the detection of different proteins expression levels. The authors would like to apologize for any inconvenience caused.
- Noble metal nanoparticles applications in cancerPublication . Conde, João; Doria, Gonçalo; Baptista, Pedro Viana; Centro de Investigação em Genética Molecular Humana (CIGMH); DCV - Departamento de Ciências da Vida; Hindawi Publishing CorporationNanotechnology has prompted new and improved materials for biomedical applications with particular emphasis in therapy and diagnostics. Special interest has been directed at providing enhanced molecular therapeutics for cancer, where conventional approaches do not effectively differentiate between cancerous and normal cells; that is, they lack specificity. This normally causes systemic toxicity and severe and adverse side effects with concomitant loss of quality of life. Because of their small size, nanoparticles can readily interact with biomolecules both at surface and inside cells, yielding better signals and target specificity for diagnostics and therapeutics. This way, a variety of nanoparticles with the possibility of diversified modification with biomolecules have been investigated for biomedical applications including their use in highly sensitive imaging assays, thermal ablation, and radiotherapy enhancement as well as drug and gene delivery and silencing. Here, we review the available noble metal nanoparticles for cancer therapy, with particular focus on those already being translated into clinical settings.
- Nanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea?Publication . Conde, João; de la Fuente, Jesus M.; Baptista, Pedro Viana; DCV - Departamento de Ciências da Vida; Centro de Investigação em Genética Molecular Humana (CIGMH); Frontiers Media
- Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicinePublication . Conde, João; Dias, Jorge T.; Grazu, Valeria; Moros, Maria; Baptista, Pedro; de la Fuente, Jesus M.; DCV - Departamento de Ciências da Vida; Centro de Investigação em Genética Molecular Humana (CIGMH); Frontiers MediaIn the last 30 years we have assisted to a massive advance of nanomaterials in material science. Nanomaterials and structures, in addition to their small size, have properties that differ from those of larger bulk materials, making them ideal for a host of novel applications. The spread of nanotechnology in the last years has been due to the improvement of synthesis and characterization methods on the nanoscale, a field rich in new physical phenomena and synthetic opportunities. In fact, the development of functional nanoparticles has progressed exponentially over the past two decades. This work aims to extensively review 30 years of different strategies of surface modification and functionalization of noble metal (gold) nanoparticles, magnetic nanocrystals and semiconductor nanoparticles, such as quantum dots. The aim of this review is not only to provide in-depth insights into the different biofunctionalization and characterization methods, but also to give an overview of possibilities and limitations of the available nanoparticles.
- Erratum: Convergent recombination cessation between mating-type genes and centromeres in selfing anther-smut fungi (Genome Research (2019) 29 (944-953) DOI: 10.1101/gr.242578.118)Publication . Carpentier, Fantin; Rodríguez de la Vega, Ricardo C.; Branco, Sara; Snirc, Alodie; Coelho, Marco A.; Hood, Michael E.; Giraud, Tatiana; UCIBIO - Applied Molecular Biosciences Unit; DCV - Departamento de Ciências da Vida; Cold Spring Harbor Laboratory PressThe authors would like to correct an error in the phylogenetic tree in Figure 5B. The labels of two species (M. silenes-acaulis and M. violaceum s. str.) were inadvertently interchanged in the initial publication of this article. The corrected figure has been updated in the revised manuscript online. The authors apologize for any confusion this may have caused.
- Nanophotonics for molecular diagnostics and therapy applicationsPublication . Conde, João; Rosa, João; Lima, João C.; Baptista, Pedro V.; Centro de Investigação em Genética Molecular Humana (CIGMH); DCV - Departamento de Ciências da Vida; DQ - Departamento de Química; CQFB-REQUIMTE - Centro de Química Fina e Biotecnologia (Lab. Associado REQUIMTE); WileyLight has always fascinated mankind and since the beginning of recorded history it has been both a subject of research and a tool for investigation of other phenomena. Today, with the advent of nanotechnology, the use of light has reached its own dimension where light-matter interactions take place at wavelength and subwavelength scales and where the physical/chemical nature of nanostructures controls the interactions. This is the field of nanophotonics which allows for the exploration and manipulation of light in and around nanostructures, single molecules, and molecular complexes. What is more is the use of nanophotonics in biomolecular interactionsnanobiophotonicshas prompt for a plethora of molecular diagnostics and therapeutics making use of the remarkable nanoscale properties. In this paper, we shall focus on the uses of nanobiophotonics for molecular diagnostics involving specific sequence characterization of nucleic acids and for gene delivery systems of relevance for therapy strategies. The use of nanobiophotonics for the combined diagnostics/therapeutics (theranostics) will also be addressed, with particular focus on those systems enabling the development of safer, more efficient, and specific platforms. Finally, the translation of nanophotonics for theranostics into the clinical setting will be discussed.